Sources
Scientific sources and medical references. The information on this page about lipoprotein(a), cardiovascular risk, and its specific impact in women is based on the following scientific publications and clinical guidelines:
Honigberg MC, Zekavat SM, Aragam K, et al.
Association of premature menopause with cardiovascular disease.
Circulation, 2019.
Provides evidence that the loss of hormonal protection in women is associated with an accelerated increase in cardiovascular risk around and after menopause.
https://pubmed.ncbi.nlm.nih.gov/30955264/
Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG.
Elevated lipoprotein(a) and risk of myocardial infarction in women and men.
Circulation, 2009.
Demonstrates that elevated Lp(a) significantly increases the risk of myocardial infarction in women as well as in men, with later but often more severe clinical presentation in women.
https://pubmed.ncbi.nlm.nih.gov/19620542/
Kronenberg F, Mora S, Stroes ESG, et al.
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
European Heart Journal, 2022.
European consensus addressing heritability, sex-specific differences, life-stage considerations, and the importance of Lp(a) measurement in women.
https://pubmed.ncbi.nlm.nih.gov/36036785/
Burgess S, Ference BA, Staley JR, et al.
Association of LPA variants with risk of coronary disease and aortic valve stenosis.
JAMA Cardiology, 2018.
Genetic evidence demonstrating a causal relationship between elevated Lp(a) and cardiovascular disease in both women and men.
https://pubmed.ncbi.nlm.nih.gov/29926099/
Visseren FLJ, Mach F, Smulders YM, et al.
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
European Heart Journal, 2021.
Clinical guidelines with explicit attention to sex differences, hereditary risk factors, and cardiovascular prevention in women.
https://pubmed.ncbi.nlm.nih.gov/34458905/

NL - Nederlands
EN - English
DE - Deutsch